Serviços Personalizados
Journal
Artigo
Links relacionados
Compartilhar
Revista Médica del Uruguay
versão impressa ISSN 0303-3295versão On-line ISSN 1688-0390
Resumo
ORELLANO, Pablo; IRASTORZA, Lorena; INTROINI, Lucia e TORRE, Wendy. Recombinant human epidermal growth factor in the treatment of diabetic foot ulcers. Rev. Méd. Urug. [online]. 2024, vol.40, n.4, e302. Epub 26-Nov-2024. ISSN 0303-3295. https://doi.org/10.29193/rmu.40.4.7.
Diabetic foot wounds are a common complication, and their treatment is a challenging task. Complex molecular alterations cause cellular dysfunction of cytokines and growth factors, which delay ulcer healing. Epidermal growth factor (EGF) plays a relevant role; however, its bioavailability is altered. Clinical research suggests that the application of recombinant human EGF (rhEGF) as an adjunct to standard treatment can achieve partial or complete healing and prevent complications.
Objective:
To communicate the results of diabetic foot ulcer treatment with rhEGF in 5 patients attended at the Foot Unit of the Public Hospital.
Material and Method:
An observational, descriptive, and retrospective study of outpatient records of diabetic patients over 18 years of age, with neuroischemic ulcers that had been delayed in healing for at least 4 weeks, treated with intradermal rhEGF between June and December 2022. Three male and two female patients were treated, with an average age of 57,8 years, with ulcers classified as Texas IIA, IIC, IIIA, and IIIC, with an initial diameter of 38 cm2. An average of 8 applications per patient of rhEGF were performed over an average of 32 days.
Results:
At 8 weeks, the mean diameter of the lesion was reduced to 8,2 cm2, with an average reduction percentage of 89%. Total closure of the lesion was achieved in all 5 patients, with 4 of them achieving this within the same period. As a side effect, 3 patients experienced pain and 2 experienced chills. There were no recurrences after one year of post-healing follow-up.
Conclusion:
The application of rhEGF in 5 patients with neuroischemic ulcers was safe and achieved effective complete tissue repair in 4 of them within 8 weeks.
Palavras-chave : Diabetic foot; Recombinant human epidermal growth factor; Heberprot-P; Diabetic foot ulcer; Wound healing.